Skip to content
value.today

Tetraphase Pharmaceuticals Inc.

Total raised
$65 M
3 rounds on record
Latest round
$10 M
Jan 2020
First round on record
Sep 2009
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tetraphase Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2020$10 MNo. 3$10 to $50 million

Tetraphase Pharmaceuticals Inc.: Raise no. 3, Jan 2020

Investors in this round

1 investor had bought by the notice of Jan 28, 2020: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Tetraphase Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Watt · Executive Officer
  • Larry Edwards · Executive Officer, Director
  • Maria Stahl · Executive Officer
  • Garen Patrick Bohlin · Director
  • Gerri G. Henwood · Director
  • Guy G. Macdonald · Director
  • Jeffrey A. Chodakewitz · Director
  • John G. Freund · Director
  • Keith G. Maher · Director
  • L. Patrick Gage · Director
  • Nancy J. Wysenski · Director
  • Steven Patrick Boyd · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. (CRD 375) · New York, New YorkSold in all US states

Signed by Maria Stahl, Chief Business Officer and General Counsel. Source: SEC Form D, newest notice filed Jan 28, 2020. Read the notice at the SEC.

equity, optionsSEC
May 2010$45 MNo. 2$10 to $50 million

Tetraphase Pharmaceuticals Inc.: Raise no. 2, May 2010

Investors in this round

14 investors had bought by the notice of May 28, 2010: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Tetraphase Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$45 M of $45 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Lubner · Executive Officer
  • Guy Macdonald · Executive Officer, Director
  • Douglas Cole · Director
  • Eric M. Gordon · Director
  • Karl D. Handelsman · Director
  • Lawrence Miller · Director
  • Robert D. Weisskoff · Director
  • Steve D. Gullans · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Guy Macdonald, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 28, 2010. Read the notice at the SEC.

equitySEC
Sep 2009$10 MNo. 1$10 to $50 million

Tetraphase Pharmaceuticals Inc.: Raise no. 1, Sep 2009

Investors in this round

9 investors had bought by the notice of Sep 23, 2009: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Tetraphase Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $30 M offered; $20 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Lubner · Executive Officer
  • Guy Macdonald · Executive Officer
  • Douglas Cole · Director
  • Eric M. Gordon · Director
  • Karl D. Handelsman · Director
  • Lawrence Miller · Director
  • Robert Weisskoff · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Guy Macdonald, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 23, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tetraphase Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2020).

    SEC Form D · Jan 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2020

That is all the official record says: Tetraphase Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the website on record does not name the company, so it was not used.

Investors#

23 named in official filings. Open an investor to see everything it has backed.

Investors in Tetraphase Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
CMEA Ventures VI GmbH & Co. KGVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Cmea Ventures VI LPVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
CMEA Ventures VI Management, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
David Charles LubnerPersonnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Excel Medical Fund LPFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Excel Medical Ventures, LLCVenture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures 2007 General Partner LLCVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures Fund 2004 L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures Fund 2007, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Flagship Ventures General Partner LLCVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Fmr LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Joaquim TriasPersonnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase (DP&UP) LLCOthernot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase II (Annex Fund) LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase II LLCOthernot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase II (Select Fund) LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase Venture Partners (DP&UP) Limited PartnershipVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase Venture Partners II (Annex Fund) Limited PartnershipVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Mediphase Venture Partners II LPVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred (Form 3, 2013)SEC Form 3
Mediphase Venture Partners II (Select Fund) Limited PartnershipVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Skyline Venture Management IV, LLCVenture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Skyline Venture Partners Qualified Purchaser Fund IV L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B and C preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Xiao-Yi XiaoPersonnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tetraphase Pharmaceuticals Inc.
NameRoleNamed in
Christopher WattExecutive officerJan 2020
Larry EdwardsExecutive officerJan 2020
Maria StahlExecutive officerJan 2020
David LubnerExecutive officerMay 2010
Guy MacdonaldExecutive officerMay 2010
Garen Patrick BohlinDirectorJan 2020
Gerri G. HenwoodDirectorJan 2020
Guy G. MacdonaldDirectorJan 2020
Jeffrey A. ChodakewitzDirectorJan 2020
John G. FreundDirectorJan 2020
Keith G. MaherDirectorJan 2020
L. Patrick GageDirectorJan 2020
Larry EdwardsDirectorJan 2020
Nancy J. WysenskiDirectorJan 2020
Steven Patrick BoydDirectorJan 2020
Douglas ColeDirectorMay 2010
Eric M. GordonDirectorMay 2010
Guy MacdonaldDirectorMay 2010
Karl D. HandelsmanDirectorMay 2010
Lawrence MillerDirectorMay 2010
Robert D. WeisskoffDirectorMay 2010
Steve D. GullansDirectorMay 2010
Robert WeisskoffDirectorSep 2009

About

Company in Watertown, United States.